Literature DB >> 35209

Pharmacology of anti-anxiety drugs with special reference to clobazam.

S Fielding, I Hoffmann.   

Abstract

1 In several studies clobazam exhibited a potency which ranges between that of chlordiazepoxide and diazepam. Its anxiolytic and anti-aggression effects are produced by doses usually ranging below those that cause disorders in motor activity. 2 This separation was demonstrable to an even greater degree with the desmethyl metabolite. The activity of the metabolite, however, was weaker than that of the original substance. 3 The advantage of clobazam compared with the 1.4 benzodiazepines lies mainly in the fact that motor activity is influenced only after very high doses, these doses being markedly above those required to induce tranquillizing and anti-agression activities. 4 Clobazam has no marked effect on the cardiovascular system, respiration of excretion.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 35209      PMCID: PMC1429504     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  [Pharmacological differentiation & evaluation of neuroleptics].

Authors:  L THER; G VOGEL; P WERNER
Journal:  Arzneimittelforschung       Date:  1959-06

2.  The influence of certain central depressants on fighting behavior of mice.

Authors:  G CHEN; B BOHNER; A C BRATTON
Journal:  Arch Int Pharmacodyn Ther       Date:  1963-03-01

3.  Ataractic suppression of isolation-induced aggressive behavior.

Authors:  C Y YEN; R L STANGER; N MILLMAN
Journal:  Arch Int Pharmacodyn Ther       Date:  1959-12-01

4.  Effects of various centrally acting drugs on fighting behavior of mice.

Authors:  R E TEDESCHI; D H TEDESCHI; A MUCHA; L COOK; P A MATTIS; E J FELLOWS
Journal:  J Pharmacol Exp Ther       Date:  1959-01       Impact factor: 4.030

5.  Increase of "antianxiety" activity and tolerance of behavioral depression during chronic administration of oxazepam.

Authors:  D L Margules; L Stein
Journal:  Psychopharmacologia       Date:  1968

6.  Additional studies on the importance of glycine and GABA in mediating the actions of benzodiazepines.

Authors:  A S Lippa; B Regan
Journal:  Life Sci       Date:  1977-12-15       Impact factor: 5.037

7.  Pharmacological and toxicological properties of clobazam (1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-diketo-3H-1,5-benzodiazepine), a new psychotherapeutic agent.

Authors:  F Barzaghi; R Fournex; P Mantegazza
Journal:  Arzneimittelforschung       Date:  1973-05
  7 in total
  7 in total

Review 1.  Clobazam: pharmacological and therapeutic profile.

Authors:  G W Hanks
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

2.  Clobazam: anticonvulsant action in animal models of epilepsy [proceedings].

Authors:  B S Meldrum; A G Chapman; R W Horton
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

3.  Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients.

Authors:  S Jawad; A Richens; J Oxley
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

4.  Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy.

Authors:  Sachiyo Hashi; Ikuko Yano; Mai Shibata; Satohiro Masuda; Masako Kinoshita; Riki Matsumoto; Akio Ikeda; Ryosuke Takahashi; Kazuo Matsubara
Journal:  Eur J Clin Pharmacol       Date:  2014-10-18       Impact factor: 2.953

5.  Antileptazol activity and kinetic of CP 1414 S (7-nitro-2-amino-5-phenyl-3-H-,1,5-benzodiazepine-4-one) in the rat and mouse.

Authors:  S Caccia; M Ballabio; M G Zanini; S Garattini; R Samanin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982       Impact factor: 2.441

6.  N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy?

Authors:  J R Haigh; T Pullar; J P Gent; C Dailley; M Feely
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

Review 7.  Clobazam: a review of its pharmacological properties and therapeutic use in anxiety.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-09       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.